Theravance Biopharma Inc [TBPH] stock prices are up 3.24% to $18.48 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The TBPH shares have gain 6.27% over the last week, with a monthly amount glided 30.69%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Theravance Biopharma Inc [NASDAQ: TBPH] stock has seen the most recent analyst activity on September 12, 2025, when B. Riley Securities initiated its Buy rating and assigned the stock a price target of $28. Previously, Leerink Partners downgraded its rating to Market Perform on August 06, 2024, and dropped its price target to $10. On April 12, 2024, BTIG Research initiated with a Buy rating and assigned a price target of $21 on the stock. Evercore ISI downgraded its rating to a In-line. SVB Leerink initiated its recommendation with an Outperform and recommended $12 as its price target on May 23, 2022. JP Morgan upgraded its rating to Neutral for this stock on November 05, 2021, but kept the price target unchanged to $12. In a note dated September 15, 2021, JP Morgan downgraded an Underweight rating on this stock but restated the target price of $7.
The stock price of Theravance Biopharma Inc [TBPH] has been fluctuating between $7.90 and $18.96 over the past year. Currently, Wall Street analysts expect the stock to reach $15.33 within the next 12 months. Theravance Biopharma Inc [NASDAQ: TBPH] shares were valued at $18.48 at the most recent close of the market. An investor can expect a potential drop of -17.05% based on the average TBPH price forecast.
Analyzing the TBPH fundamentals
The Theravance Biopharma Inc [NASDAQ:TBPH] reported sales of 80.33M for trailing twelve months, representing a surge of 18.51%. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -0.41%, Pretax Profit Margin comes in at 0.59%, and Net Profit Margin reading is 0.2%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.08 and Total Capital is -0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.80 points at the first support level, and at 17.11 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.87, and for the 2nd resistance point, it is at 19.25.
Ratios To Look Out For
It’s worth pointing out that Theravance Biopharma Inc [NASDAQ:TBPH]’s Current Ratio is 9.48. On the other hand, the Quick Ratio is 9.48, and the Cash Ratio is 4.67. Considering the valuation of this stock, the price to sales ratio is 11.66, the price to book ratio is 4.02 and price to earnings (TTM) ratio is 32.85.
Transactions by insiders
Recent insider trading involved ERAN BROSHY, Director, that happened on Nov 11 ’25 when 45000.0 shares were purchased. SVP, COMM & MEDICAL AFFAIRS, Farnum Rhonda completed a deal on Jul 14 ’25 to sell 10000.0 shares. Meanwhile, Officer RHONDA FARNUM bought 10000.0 shares on Jul 14 ’25.
